Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

New Targeted Antibody Shows Promise for Advanced Urothelial Cancer

June 3rd 2019

After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.

Friday Frontline: May 31, 2019

May 31st 2019

From today’s top performers to the latest in scientific research, here’s what is making headlines in the cancer space this week.

Friday Frontline: May 24, 2019

May 24th 2019

From World Blood Cancer Day to today’s top performers fundraising for lifesaving research, here’s what’s making headlines in the cancer space this week.

Non-Invasive Urine Tests Show Promise in Bladder Cancer Detection, Monitoring

May 17th 2019

With no available diagnostic tests for the detection and/or monitoring of bladder cancer, researchers from the Medical College of Georgia at Augusta University may have two new urine tests that determine the disease’s severity and detect for its recurrence.

Bladder Cancer Awareness Month: Understanding Risk for Earlier Detection

May 16th 2019

May is recognized as Bladder Cancer Awareness Month. Know the facts and statistics in order to understand your risk for the disease and take preventative actions to guard your health.

Smoking Cessation Programs Help Reduce Bladder Cancer Risk in Older Women

May 15th 2019

A recent study showed that postmenopausal women demonstrated a significant reduction in the risk for bladder cancer after quitting smoking, highlighting the need for prevention and cessation programs in older women.

Genomic Profiling May Translate to Personalized Treatment for Bladder Cancer Subtypes

May 14th 2019

Researchers at Baylor College of Medicine found that a particular subgroup of patients with advanced bladder cancer, identified with a computational tool, responded to immunotherapy.

The Role of Mental Health in Cancer Outcomes

April 24th 2019

A person’s pre-existing mental state may negatively influence their health, but professional support can help maintain the best mindset, say researchers.

Age at Menopause May Play a Role in Bladder Cancer Risk

April 16th 2019

Researchers found that women who went into menopause before 45 years old were at greater risk for bladder cancer than women who experienced it later.

Updates to Bladder Cancer Treatment Guidelines Offer Hope

April 16th 2019

After more than 30 years of relative stability, the treatment landscape for urothelial cancer has seen updates in recent years that provide hope for patients.

Non-Muscle Invasive Bladder Cancer Survivors Experience PTSD Symptoms

April 12th 2019

According to survey results, almost 30% of non-muscle invasive bladder cancer survivors experienced at least one PTSD symptom.

FDA Approves First Targeted Therapy to Treat Metastatic Bladder Cancer

April 12th 2019

The Food and Drug Administration granted accelerated approval to Balversa to treat locally advanced or metastatic bladder cancer with a type of susceptible genetic alterations known as FGFR3 or FGFR2, in patients who have progressed during or following prior platinum-containing chemotherapy.

Investigational Therapy Shows Promise in Advanced Bladder Cancer

April 11th 2019

A percentage of patients with urothelial carcinoma saw their disease shrink or disappear after treatment with enfortumab vedotin in a phase 2 clinical trial.

The Future of Immunotherapy for Bladder Cancer

March 14th 2019

An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.

Frequent Infections May Lead to Delayed Cancer Diagnoses in Women

March 13th 2019

Women with frequent urinary tract infections (UTIs) were more likely to experience lower quality diagnostic processes when it comes to screening for bladder and kidney cancer.

Radical Cystectomy: Risk Versus Reward for Patients With Bladder Cancer

March 13th 2019

Although muscle-invasive disease is often treated by removal of the bladder, experts reveal potential high risk of death.

Past, Present and Future: 'Immunotherapy is Here to Stay'

March 12th 2019

At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.

Mediterranean Diet Associated With Lower Risk of Bladder Cancer

March 11th 2019

After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.

Highly Sensitive Urine Test Could Be a Better, Less Invasive Tool for Bladder Cancer

February 22nd 2019

Using tumor DNA found in urine, researchers believe they have found a method to diagnose and monitor bladder cancer that outperforms standard tests.

Keytruda May Play a Role in Treatment of Patients with Non-Muscle Invasive Bladder Cancer

February 21st 2019

After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.

FGFR3 Inhibitor Shows Promise in Advanced Bladder Cancer

February 20th 2019

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

Computer Model May 'Offer Better Picture' of Who Benefits from Bladder Cancer Therapy

February 13th 2019

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

Bladder Cancer Treatment Without Removing the Organ is Effective

January 18th 2019

Although chemotherapy and radical cystectomy are traditionally used to treat muscle-invasive disease, a recent analysis shows similar overall survival outcomes in patients treated with chemoradiotherapy.

Risk for Heart Attack, Stroke Five-Fold in Older Patients One Month Before Cancer Diagnosis

January 18th 2019

Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

January 10th 2019

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Clinical Trials Play Key Role in Future of Bladder Cancer

November 29th 2018

While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.

New Chemotherapy Combination Offers Improved Outcomes in Bladder Cancer

November 27th 2018

Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.

Treatment Options for Bladder Cancer: What's New and What's Next

November 26th 2018

The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

Managing Bladder Cancer in the Era of Cancer Immunotherapy

November 26th 2018

Although immunotherapies show promise for patients, there are still challenges ahead.

Combination with Higher Dose of Yervoy Shows Promise in Bladder Cancer

November 6th 2018

Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.